CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry. 2013

Kiyoko Kawamura, and Kenzo Hiroshima, and Takeo Suzuki, and Kuan Chai, and Naoto Yamaguchi, and Masato Shingyoji, and Toshikazu Yusa, and Yuji Tada, and Yuichi Takiguchi, and Koichiro Tatsumi, and Hideaki Shimada, and Masatoshi Tagawa
Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba 260-8717, Japan; e-mail: mtagawa@chiba-cc.jp.

OBJECTIVE To pathologically distinguish mesothelioma from lung carcinoma, particularly adenocarcinoma. METHODS We conducted immunohistochemical analyses on clinical specimens, including 26 cases of mesothelioma, 28 cases of lung adenocarcinoma, and 33 cases of lung squamous cell carcinoma. RESULTS We found that CD90 expression was useful in making a differential diagnosis between epithelioid mesothelioma and lung adenocarcinoma, whereas sarcomatoid mesothelioma and lung carcinoma specimens, irrespective of the histologic types, were negative in general. The sensitivity and specificity of CD90 expression in epithelioid mesothelioma and lung adenocarcinoma were comparable to those of well-established markers used for the differential diagnosis. CONCLUSIONS These data collectively indicate that CD90 is a novel diagnostic marker that contributes to a diagnosis of epithelioid mesothelioma.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008654 Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed) Mesotheliomas
D010997 Pleural Neoplasms Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms. Neoplasms, Pleural,Neoplasm, Pleural,Pleural Neoplasm
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D018800 Thy-1 Antigens A group of differentiation surface antigens, among the first to be discovered on thymocytes and T-lymphocytes. Originally identified in the mouse, they are also found in other species including humans, and are expressed on brain neurons and other cells. Antigens, CD90,Antigens, Thy-1,CD90 Antigens,CD90 Antigen,Thy-1 Antigen,Thy-1.1 Antigen,Thy-1.2 Antigen,Antigen, CD90,Antigen, Thy-1,Antigen, Thy-1.1,Antigen, Thy-1.2,Antigens, Thy 1,Thy 1 Antigen,Thy 1 Antigens,Thy 1.1 Antigen,Thy 1.2 Antigen

Related Publications

Kiyoko Kawamura, and Kenzo Hiroshima, and Takeo Suzuki, and Kuan Chai, and Naoto Yamaguchi, and Masato Shingyoji, and Toshikazu Yusa, and Yuji Tada, and Yuichi Takiguchi, and Koichiro Tatsumi, and Hideaki Shimada, and Masatoshi Tagawa
August 2017, Cancer cytopathology,
Kiyoko Kawamura, and Kenzo Hiroshima, and Takeo Suzuki, and Kuan Chai, and Naoto Yamaguchi, and Masato Shingyoji, and Toshikazu Yusa, and Yuji Tada, and Yuichi Takiguchi, and Koichiro Tatsumi, and Hideaki Shimada, and Masatoshi Tagawa
December 2017, Histopathology,
Kiyoko Kawamura, and Kenzo Hiroshima, and Takeo Suzuki, and Kuan Chai, and Naoto Yamaguchi, and Masato Shingyoji, and Toshikazu Yusa, and Yuji Tada, and Yuichi Takiguchi, and Koichiro Tatsumi, and Hideaki Shimada, and Masatoshi Tagawa
May 2018, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Kiyoko Kawamura, and Kenzo Hiroshima, and Takeo Suzuki, and Kuan Chai, and Naoto Yamaguchi, and Masato Shingyoji, and Toshikazu Yusa, and Yuji Tada, and Yuichi Takiguchi, and Koichiro Tatsumi, and Hideaki Shimada, and Masatoshi Tagawa
June 2021, Scientific reports,
Kiyoko Kawamura, and Kenzo Hiroshima, and Takeo Suzuki, and Kuan Chai, and Naoto Yamaguchi, and Masato Shingyoji, and Toshikazu Yusa, and Yuji Tada, and Yuichi Takiguchi, and Koichiro Tatsumi, and Hideaki Shimada, and Masatoshi Tagawa
January 2022, Combinatorial chemistry & high throughput screening,
Kiyoko Kawamura, and Kenzo Hiroshima, and Takeo Suzuki, and Kuan Chai, and Naoto Yamaguchi, and Masato Shingyoji, and Toshikazu Yusa, and Yuji Tada, and Yuichi Takiguchi, and Koichiro Tatsumi, and Hideaki Shimada, and Masatoshi Tagawa
March 2000, British journal of cancer,
Kiyoko Kawamura, and Kenzo Hiroshima, and Takeo Suzuki, and Kuan Chai, and Naoto Yamaguchi, and Masato Shingyoji, and Toshikazu Yusa, and Yuji Tada, and Yuichi Takiguchi, and Koichiro Tatsumi, and Hideaki Shimada, and Masatoshi Tagawa
January 2019, Iranian journal of pathology,
Kiyoko Kawamura, and Kenzo Hiroshima, and Takeo Suzuki, and Kuan Chai, and Naoto Yamaguchi, and Masato Shingyoji, and Toshikazu Yusa, and Yuji Tada, and Yuichi Takiguchi, and Koichiro Tatsumi, and Hideaki Shimada, and Masatoshi Tagawa
January 2009, The International journal of biological markers,
Kiyoko Kawamura, and Kenzo Hiroshima, and Takeo Suzuki, and Kuan Chai, and Naoto Yamaguchi, and Masato Shingyoji, and Toshikazu Yusa, and Yuji Tada, and Yuichi Takiguchi, and Koichiro Tatsumi, and Hideaki Shimada, and Masatoshi Tagawa
March 2012, Archives of pathology & laboratory medicine,
Kiyoko Kawamura, and Kenzo Hiroshima, and Takeo Suzuki, and Kuan Chai, and Naoto Yamaguchi, and Masato Shingyoji, and Toshikazu Yusa, and Yuji Tada, and Yuichi Takiguchi, and Koichiro Tatsumi, and Hideaki Shimada, and Masatoshi Tagawa
July 2017, Pathology oncology research : POR,
Copied contents to your clipboard!